全面分析老年非胰岛素依赖型糖尿病患者的抗糖尿病药物相互作用

Q2 Pharmacology, Toxicology and Pharmaceutics International Journal of Applied Pharmaceutics Pub Date : 2024-02-15 DOI:10.22159/ijap.2024.v16s1.12
Rahmi Yosmar, Eugenia Shepany, Najmiatul Fitria
{"title":"全面分析老年非胰岛素依赖型糖尿病患者的抗糖尿病药物相互作用","authors":"Rahmi Yosmar, Eugenia Shepany, Najmiatul Fitria","doi":"10.22159/ijap.2024.v16s1.12","DOIUrl":null,"url":null,"abstract":"Objective: Type 2 diabetes mellitus (DM) is a disease that is the leading cause of blindness, heart disease, and kidney failure. Geriatric patients with type 2 DM and complications require multiple medications (polypharmacy), contributing to drug-drug interactions (DDIs). DDIs can affect the clinical outcome of patients. This study aims to analyze potential drug-drug interactions based on the mechanism and severity, determine the relationship between the number of medications and potential drug interaction, and determine the relationship between polypharmacy and the severity of clinical outcomes. \nMethods: This was an analytical observational with retrospective data collection through patient medical records of hospitalized patients treated with an antidiabetic and one or more other drugs that met the inclusion criteria, involving 81 patients using total sampling. \nResults: The result showed that out of 81 patients, there were 59 patients who potentially experienced drug-drug interactions (72.8%) with a total of 162 cases of drug interactions, and the most prevalent interaction mechanism was pharmacodynamic (84.0%) with a moderate severity level (57.4%). There was a significant relationship between the number of medications and potential drug-drug interactions (p<0.05). At the same time, there was no meaningful relationship between polypharmacy and the severity of drug interactions with clinical outcomes (p>0.05). \nConclusion: An increase in the number of drugs is a predictor of drug interactions. Although drug interactions may theoretically occur, not all interactions will significantly affect patients.","PeriodicalId":13737,"journal":{"name":"International Journal of Applied Pharmaceutics","volume":"11 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A COMPREHENSIVE ANALYSIS OF ANTIDIABETIC DRUG INTERACTIONS IN GERIATRIC NON-INSULIN DEPENDENT DIABETES MELLITUS PATIENTS\",\"authors\":\"Rahmi Yosmar, Eugenia Shepany, Najmiatul Fitria\",\"doi\":\"10.22159/ijap.2024.v16s1.12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Type 2 diabetes mellitus (DM) is a disease that is the leading cause of blindness, heart disease, and kidney failure. Geriatric patients with type 2 DM and complications require multiple medications (polypharmacy), contributing to drug-drug interactions (DDIs). DDIs can affect the clinical outcome of patients. This study aims to analyze potential drug-drug interactions based on the mechanism and severity, determine the relationship between the number of medications and potential drug interaction, and determine the relationship between polypharmacy and the severity of clinical outcomes. \\nMethods: This was an analytical observational with retrospective data collection through patient medical records of hospitalized patients treated with an antidiabetic and one or more other drugs that met the inclusion criteria, involving 81 patients using total sampling. \\nResults: The result showed that out of 81 patients, there were 59 patients who potentially experienced drug-drug interactions (72.8%) with a total of 162 cases of drug interactions, and the most prevalent interaction mechanism was pharmacodynamic (84.0%) with a moderate severity level (57.4%). There was a significant relationship between the number of medications and potential drug-drug interactions (p<0.05). At the same time, there was no meaningful relationship between polypharmacy and the severity of drug interactions with clinical outcomes (p>0.05). \\nConclusion: An increase in the number of drugs is a predictor of drug interactions. Although drug interactions may theoretically occur, not all interactions will significantly affect patients.\",\"PeriodicalId\":13737,\"journal\":{\"name\":\"International Journal of Applied Pharmaceutics\",\"volume\":\"11 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Applied Pharmaceutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22159/ijap.2024.v16s1.12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Applied Pharmaceutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22159/ijap.2024.v16s1.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

目的:2 型糖尿病(DM)是导致失明、心脏病和肾衰竭的主要疾病。患有 2 型糖尿病和并发症的老年患者需要服用多种药物(多药治疗),从而导致药物间相互作用(DDI)。DDIs 会影响患者的临床疗效。本研究旨在根据药物相互作用的机制和严重程度分析潜在的药物相互作用,确定药物数量与潜在药物相互作用之间的关系,并确定多药治疗与临床结局严重程度之间的关系。研究方法这是一项分析观察性研究,通过符合纳入标准的住院患者的病历收集回顾性数据,涉及 81 名患者,采用总体抽样法。结果显示结果显示,在 81 名患者中,有 59 名患者(72.8%)可能发生过药物间相互作用,共计 162 例,最普遍的相互作用机制是药效学(84.0%),严重程度为中度(57.4%)。药物数量与潜在的药物相互作用之间存在明显关系(P0.05)。结论药物数量的增加是药物相互作用的一个预测因素。虽然理论上可能会发生药物相互作用,但并非所有的相互作用都会对患者产生重大影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A COMPREHENSIVE ANALYSIS OF ANTIDIABETIC DRUG INTERACTIONS IN GERIATRIC NON-INSULIN DEPENDENT DIABETES MELLITUS PATIENTS
Objective: Type 2 diabetes mellitus (DM) is a disease that is the leading cause of blindness, heart disease, and kidney failure. Geriatric patients with type 2 DM and complications require multiple medications (polypharmacy), contributing to drug-drug interactions (DDIs). DDIs can affect the clinical outcome of patients. This study aims to analyze potential drug-drug interactions based on the mechanism and severity, determine the relationship between the number of medications and potential drug interaction, and determine the relationship between polypharmacy and the severity of clinical outcomes. Methods: This was an analytical observational with retrospective data collection through patient medical records of hospitalized patients treated with an antidiabetic and one or more other drugs that met the inclusion criteria, involving 81 patients using total sampling. Results: The result showed that out of 81 patients, there were 59 patients who potentially experienced drug-drug interactions (72.8%) with a total of 162 cases of drug interactions, and the most prevalent interaction mechanism was pharmacodynamic (84.0%) with a moderate severity level (57.4%). There was a significant relationship between the number of medications and potential drug-drug interactions (p<0.05). At the same time, there was no meaningful relationship between polypharmacy and the severity of drug interactions with clinical outcomes (p>0.05). Conclusion: An increase in the number of drugs is a predictor of drug interactions. Although drug interactions may theoretically occur, not all interactions will significantly affect patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Applied Pharmaceutics
International Journal of Applied Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
1.40
自引率
0.00%
发文量
219
期刊介绍: International Journal of Applied Pharmaceutics (Int J App Pharm) is a peer-reviewed, bimonthly (onward March 2017) open access journal devoted to the excellence and research in the pure pharmaceutics. This Journal publishes original research work that contributes significantly to further the scientific knowledge in conventional dosage forms, formulation development and characterization, controlled and novel drug delivery, biopharmaceutics, pharmacokinetics, molecular drug design, polymer-based drug delivery, nanotechnology, nanocarrier based drug delivery, novel routes and modes of delivery; responsive delivery systems, prodrug design, development and characterization of the targeted drug delivery systems, ligand carrier interactions etc. However, the other areas which are related to the pharmaceutics are also entertained includes physical pharmacy and API (active pharmaceutical ingredients) analysis. The Journal publishes original research work either as a Original Article or as a Short Communication. Review Articles on a current topic in the said fields are also considered for publication in the Journal.
期刊最新文献
DEVELOPMENT, OPTIMIZATION AND IN VITRO CHARACTERIZATION OF HALOPERIDOL NANOCRYSTALS USING 32 FACTORIAL DESIGN ANALYTICAL TECHNIQUES FOR DETERMINATION OF MIRABEGRON FROM BULK, PHARMACEUTICAL FORMULATION, AND BIOLOGICAL MATRICES: A CRITICAL REVIEW FORMULATION AND EVALUATION OF RED GINGER RHIZOME EXTRACT SOAP AS AN ANTIBACTERIAL THE APPLICATION OF BIOANALYTICAL METHOD OF TAMOXIFEN AND ITS ACTIVE METABOLITES FOR THERAPEUTIC DRUG MONITORING IN BREAST CANCER PATIENTS: A REVIEW RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF CURCUMIN AND RESVERATROL IN NANO-MICELLE: DUAL DRUG DUAL FORM SIMULTANEOUS ESTIMATION
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1